言語を選択

alpha-Galactosidase A

お問い合わせ

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Alemtuzumab biosimilar (Zhangjiang Biotechnology)		Phase 2 Clinical	Shanghai Zhangjiang Biotechnology Co Ltd	Leukemia, Lymphocytic, Chronic, B-Cell	詳細
ALLO-647	ALLO-647	Phase 2 Clinical	Allogene Therapeutics Inc	Lymphoma, B-Cell; Carcinoma, Renal Cell; Multiple Myeloma; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell	詳細
Recombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology)		Phase 1 Clinical	Lanzhou Institute Of Biological Products Co Ltd, Shanghai Taiyin Biotechnology Co Ltd	Leukemia, B-Cell; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Prolymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell	詳細
Alemtuzumab biosimilar(BioXpress)	BX-1523; BXT-1523	Clinical	Bioxpress Therapeutics Sa	Multiple Sclerosis; Leukemia, B-Cell	詳細

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Alemtuzumab	LDP-03; GZ-402673	Approved	Genzyme Corp, Bayer AG	Campath, Lemtrada, MabCampath	United States	Multiple Sclerosis	Genzyme Corp	2001-05-07	Myositis, Inclusion Body; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Waldenstrom Macroglobulinemia; Lymphoma; Leukemia, Prolymphocytic, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Lymphoproliferative Disorders; Peritoneal Neoplasms; Sezary Syndrome; Pancytopenia; Lymphoma, T-Cell, Peripheral; Multiple Sclerosis; Rejection of organ transplantation; Leukemia-Lymphoma, Adult T-Cell; Myelodysplastic Syndromes; Hodgkin Disease; Graft vs Host Disease; Kidney Diseases; Rejection of renal transplantation; Hematologic Neoplasms; Ovarian Neoplasms; Diabetes Mellitus, Type 1; Bone marrow transplant rejection; Leukemia; Multiple Sclerosis, Relapsing-Remitting	詳細